샘플 요청 목록

 카트 문의
시장보고서
상품코드
1758183

세계의 게실염 시장

Diverticulitis Disease
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 294 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 게실염 시장은 2030년까지 26억 달러에 도달

2024년에 18억 달러로 추정되는 세계의 게실염 시장은 2024-2030년의 분석 기간에 CAGR 6.7%로 성장하며, 2030년에는 26억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 약물 치료는 CAGR 5.8%를 기록하며, 분석 기간 종료시에는 6억 6,610만 달러에 달할 것으로 예측됩니다. 수술 치료 부문의 성장률은 분석 기간 중 CAGR 5.5%로 추정됩니다.

미국 시장은 4억 8,910만 달러로 추정, 중국은 CAGR 10.3%로 성장 예측

미국의 게실염 시장은 2024년에 4억 8,910만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 5억 4,230만 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 10.3%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.4%와 6.4%로 예측됩니다. 유럽에서는 독일이 CAGR 4.4%로 성장할 것으로 예측됩니다.

세계의 게실염 시장 - 주요 동향과 촉진요인 정리

게실염이 전 세계에서 주목받는 이유

세계 게실염 시장은 소화기 질환의 유병률 증가와 효과적인 치료 솔루션에 대한 수요 증가로 인해 관심이 높아지고 있습니다. 소화관 게실의 염증과 감염을 특징으로 하는 질환인 게실염은 특히 고령화 인구 집단과 서유럽식 식습관을 채택한 지역에서 흔하게 발생하고 있습니다. 좌식 생활습관, 섬유질이 적은 식단, 비만은 이 질환의 발병률 증가에 중요한 요인으로 작용하고 있습니다. 전 세계에서 의료 시스템의 진단 능력이 향상됨에 따라 더 많은 사례가 조기에 발견되어 의료 개입이 필요한 환자층이 확대되고 있습니다. 합병증이 없는 경우부터 수술이 필요한 경우까지 이 질환의 임상 스펙트럼은 항생제, 항염증약, 식습관 개선, 그리고 최근에는 고급 수술적 치료까지 포함할 정도로 광범위해지고 있습니다. 의료 자원에 대한 부담 증가와 고령화로 인해 게실염은 특히 선진국에서 임상적 긴급성과 상업적 기회를 동시에 제공하는 질환으로 자리매김하고 있습니다.

인구통계학적 변화에 따라 진단과 치료는 어떻게 진화하고 있는가?

영상 진단 기술과 진단 방법의 급속한 발전으로 게실염을 보다 정확하게 발견하고 분류할 수 있게 되었으며, 이는 표적 치료에 매우 중요한 역할을 합니다. 고해상도 CT 스캔과 대장내시경 검사는 이제 표준 진단 수단으로, 단순한 경우와 복잡한 경우를 구별할 수 있게 되었습니다. 치료 측면에서는 특히 경증에서 중등도의 경우 비침습적이고 외래적인 관리 전략으로 크게 전환되고 있습니다. 항생제 스튜어드십 프로그램은 의사들이 불필요한 항생제 사용을 제한하도록 장려하고, 치료 프로토콜을 개선하는 데 도움을 주고 있습니다. 동시에, 부작용이 적고 표적화된 완화를 제공할 수 있는 새로운 항염증약 및 생물제제의 연구도 진행되고 있습니다. 심한 경우에는 복강경 절제술과 같은 최소 침습적 수술이 보편화되어 입원 기간과 회복 시간이 단축되고 있습니다. 영양요법이나 식이섬유 보충도 재발 예방에 중요한 역할을 하고 있으며, 이러한 측면이 환자 관리 계획에 포함되고 있습니다. 이처럼 더 나은 진단법과 다양한 치료법이 융합되면서 전 세계에서 게실염의 표준 치료법이 재구성되고 있습니다.

게실염 솔루션에 대한 수요를 주도하는 인구와 시장은?

북미와 유럽은 게실염 치료 분야에서 가장 성숙한 시장으로, 높은 유병률, 잘 구축된 의료 인프라, 환자와 의료진 모두에 대한 인식이 높은 것이 주요 원인입니다. 특히 미국은 식생활 패턴과 베이비붐 세대의 고령화로 인해 가장 높은 유병률을 보이고 있습니다. 유럽은 그 뒤를 이어 독일, 영국 등의 국가들이 검진 및 수술 프로그램을 잘 시행하고 있습니다. 아시아태평양은 도시화, 가처분 소득 증가, 의료 서비스 접근성 향상으로 인해 시장이 빠르게 성장하고 있습니다. 인도, 중국 등 신흥 시장에서는 식습관 및 라이프스타일의 변화로 인해 환자 수가 꾸준히 증가하고 있습니다. 이들 지역에서는 병원 인프라 구축과 의료 교육에 대한 투자가 진행되어 진단 및 치료 능력이 향상되고 있습니다. 라틴아메리카와 중동은 위장관 의료에 대한 인식이 높아지고 투자가 증가하고 있는 신흥 시장입니다. 모든 지역에서 개별화된 가치 기반 치료 모델에 대한 수요가 치료 패턴과 상환 전략에 영향을 미치고 있습니다.

시장 성장을 가속하는 주요 요인은 무엇인가?

게실염 시장의 성장은 특히 도시 지역의 고령화와 식습관 변화에 따른 소화기 질환의 유병률 증가 등 여러 요인에 기인합니다. 영상 진단 기술의 발전과 대장내시경 검사에 대한 접근성 향상으로 보다 빠르고 정확한 진단이 가능해져 치료 대상 환자층이 확대되고 있습니다. 보존적 관리를 강조하는 임상 가이드라인의 변화로 인해 의약품의 역할이 증대되고 있으며, 이는 제약사에게 비즈니스 기회를 가져다주고 있습니다. 동시에 최소침습 수술의 확대는 수술 기구와 로봇 시스템에 대한 수요를 증가시키고 있습니다. 환자들의 인식이 높아지면서 의료 문해력이 향상되고 외래 치료에 대한 수요가 증가함에 따라 의료 환경 전반에서 게실염을 관리하는 방식이 재편되고 있습니다. 염증과 장내세균총 조절을 목표로 하는 새로운 의약품의 개발도 치료 파이프라인의 혁신을 촉진하고 있습니다. 또한 소화기 치료를 보다 광범위한 만성질환 관리의 틀에 통합하는 것은 전 세계 의료 시스템에서 전략적 중요성을 더욱 강화하고 있습니다.

부문

치료(투약 치료, 수술 치료, 지지요법 치료, 항생제 치료, 식이보충제 치료, 기타 치료), 최종 사용(전문 시설 최종 사용, 병원 최종 사용, 연구 시설 최종 사용)

조사 대상 기업의 예(주목 합계 48사)

  • Abbott Laboratories
  • Allergan(AbbVie)
  • AstraZeneca
  • Bausch Health Companies
  • Baxter International
  • Bristol-Myers Squibb
  • Ferring Pharmaceuticals
  • Gilead Sciences
  • GlaxoSmithKline(GSK)
  • Johnson & Johnson
  • Medtronic
  • Mylan(Viatris)
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Sandoz(Novartis)
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • UCB

AI 통합

우리는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유 SLM을 조회하는 일반적인 규범을 따르는 대신에 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.09

Global Diverticulitis Disease Market to Reach US$2.6 Billion by 2030

The global market for Diverticulitis Disease estimated at US$1.8 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Medications Treatment, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$666.1 Million by the end of the analysis period. Growth in the Surgery Treatment segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$489.1 Million While China is Forecast to Grow at 10.3% CAGR

The Diverticulitis Disease market in the U.S. is estimated at US$489.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$542.3 Million by the year 2030 trailing a CAGR of 10.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Diverticulitis Disease Market - Key Trends & Drivers Summarized

Why Is Diverticulitis Garnering Growing Medical Attention Worldwide?

The global diverticulitis disease market is experiencing heightened interest due to the increasing prevalence of gastrointestinal disorders and the rising demand for effective treatment solutions. Diverticulitis, a condition characterized by inflammation or infection of diverticula in the digestive tract, is becoming more common, particularly in aging populations and in regions adopting Western dietary habits. Sedentary lifestyles, low-fiber diets, and obesity are significant contributing factors to the rise in incidence. As healthcare systems globally improve diagnostic capabilities, more cases are being identified at earlier stages, leading to a broader patient base in need of medical intervention. The clinical spectrum of the disease-from uncomplicated cases to those requiring surgical procedures-has expanded the therapeutic landscape, encompassing antibiotics, anti-inflammatory medications, dietary modifications, and increasingly, advanced surgical treatments. The growing burden on healthcare resources, coupled with an aging demographic, has positioned diverticulitis as a condition of both clinical urgency and commercial opportunity, especially in developed nations.

How Are Diagnostics and Treatments Evolving in Response to Changing Demographics?

Rapid advancements in imaging technologies and diagnostic procedures are enabling more accurate detection and classification of diverticulitis, which is crucial for targeted treatment. High-resolution CT scans and colonoscopies are now standard diagnostic tools, allowing for differentiation between simple and complicated cases. On the treatment front, there is a significant shift toward non-invasive and outpatient management strategies, especially for mild to moderate cases. Antibiotic stewardship programs are encouraging physicians to limit unnecessary antibiotic use, leading to refined treatment protocols. Simultaneously, research is ongoing into novel anti-inflammatory agents and biologics that could provide targeted relief with fewer side effects. In severe cases, minimally invasive surgeries like laparoscopic resection are becoming more common, reducing hospital stays and recovery times. Nutritional therapy and fiber supplementation also play essential roles in recurrence prevention, and these aspects are being increasingly integrated into patient management plans. This confluence of better diagnostics and diversified treatments is reshaping the standard of care for diverticulitis worldwide.

Which Populations and Markets Are Driving Demand for Diverticulitis Solutions?

North America and Europe are the most mature markets for diverticulitis treatment, primarily due to high disease prevalence, established healthcare infrastructure, and strong awareness among both patients and practitioners. The United States, in particular, exhibits the highest incidence rates, attributed to dietary patterns and aging baby boomers. Europe follows closely, with countries like Germany and the UK implementing robust screening and surgical programs. In Asia-Pacific, the market is expanding rapidly due to urbanization, increasing disposable incomes, and greater access to healthcare services. Emerging markets such as India and China are witnessing a steady rise in cases, driven by shifts in diet and lifestyle. These regions are also investing in hospital infrastructure and medical training, leading to improved diagnostic and treatment capabilities. Latin America and the Middle East are nascent markets with rising awareness and increasing investments in gastrointestinal care. Across all regions, the demand for personalized and value-based care models is influencing treatment patterns and reimbursement strategies.

What Are the Key Factors Driving Market Growth?

The growth in the diverticulitis disease market is driven by several factors, including the rising prevalence of gastrointestinal disorders associated with aging populations and dietary changes, particularly in urbanized areas. Advances in diagnostic imaging technologies and increased access to colonoscopy screenings are enabling earlier and more accurate diagnoses, expanding the base of treated patients. Changes in clinical guidelines emphasizing conservative management have increased the role of pharmaceuticals, creating opportunities for drug manufacturers. Simultaneously, the expansion of minimally invasive surgical techniques has boosted the demand for surgical instruments and robotic systems. Growing patient awareness, combined with greater health literacy and demand for outpatient care, is reshaping the way diverticulitis is managed across healthcare settings. The development of new pharmaceutical agents targeting inflammation and gut microbiota modulation is also fueling innovation in the treatment pipeline. Moreover, the integration of gastrointestinal care into broader chronic disease management frameworks is reinforcing its strategic importance within global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Diverticulitis Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment, Other Treatments); End-Use (Specialty Centers End-Use, Hospitals End-Use, Research Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abbott Laboratories
  • Allergan (AbbVie)
  • AstraZeneca
  • Bausch Health Companies
  • Baxter International
  • Bristol-Myers Squibb
  • Ferring Pharmaceuticals
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Medtronic
  • Mylan (Viatris)
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Sandoz (Novartis)
  • Takeda Pharmaceutical
  • Teva Pharmaceutical
  • UCB

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Diverticulitis Disease - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Digestive Disorders Drives Market for Diverticulitis Treatment
    • Aging Global Population Spurs Growth in Diverticulitis Diagnoses and Therapies
    • Increasing Use of Minimally Invasive Surgical Techniques Strengthens Treatment Options
    • Advances in Imaging and Diagnostic Tools Propel Early Detection Rates
    • Growing Awareness Campaigns Highlight Disease Management and Drive Patient Volumes
    • Lifestyle Changes and Poor Dietary Habits Sustain Disease Incidence
    • High Demand for Personalized Medicine Expands Market for Targeted Therapies
    • Availability of Advanced Antibiotics Enhances Recovery Outcomes and Drives Adoption
    • Integration of AI and Predictive Analytics in Diagnostics Generates Growth Potential
    • Increased Healthcare Spending in Developing Regions Expands Access to Treatment
    • Innovation in Biologic and Anti-Inflammatory Drugs Strengthens Pipeline Prospects
    • Recurrence Prevention Strategies Drive Demand for Long-Term Management Therapies
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Diverticulitis Disease Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Diverticulitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Diverticulitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Diverticulitis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Medications Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Medications Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Medications Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Supportive Care Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Supportive Care Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Supportive Care Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Antibiotics Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Dietary Supplements Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Dietary Supplements Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Dietary Supplements Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Specialty Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Research Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Research Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: China 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Diverticulitis Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Diverticulitis Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Diverticulitis Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: France 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: UK 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Spain 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Russia 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Diverticulitis Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Diverticulitis Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Diverticulitis Disease by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: Australia 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: India 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: South Korea 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Diverticulitis Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Diverticulitis Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Diverticulitis Disease by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Latin America 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Argentina 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Brazil 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Mexico 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Diverticulitis Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Diverticulitis Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Diverticulitis Disease by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Middle East 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Iran 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Israel 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: UAE 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Diverticulitis Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Diverticulitis Disease by Treatment - Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Diverticulitis Disease by Treatment - Percentage Breakdown of Value Sales for Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment and Other Treatments for the Years 2014, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Diverticulitis Disease by End-Use - Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 217: Africa 16-Year Perspective for Diverticulitis Disease by End-Use - Percentage Breakdown of Value Sales for Specialty Centers End-Use, Hospitals End-Use and Research Centers End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제